On June 26, Finnegan client Cumberland Pharmaceuticals filed suit against Sagent Pharmaceuticals Inc. and Sagent Agila LLC, in response to the Sagent companies’ ANDA application seeking approval to market a generic version of Cumberland’s Acetadote®. Cumberland holds U.S. Patent No. 8,148,356, which covers the next generation formula of its Acetadote® product through 2025. Cumberland is represented by Finnegan in this matter.
Award/Ranking
Linda Thayer Receives Posthumous 2023 Women, Influence & Power in Law Lifetime Achievement Award
October 19, 2023
Press Release
Finnegan Adds Jenevieve Maerker to Its Trademark, Copyright, and Advertising Practice
April 19, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.